Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Skin Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 6Temozolomide 3Biopsy 3Bevacizumab 3posaconazole 2fluciclovine F-18 2Topotecan 2Specimen Handling 2Radiosurgery 2Pemetrexed 2Nivolumab 2Methotrexate 2Ketoconazole 2Fluorodeoxyglucose F18 2ribociclib 1relatlimab 1mycophenolic adenine dinucleotide 1montelukast 1gancotamab 1fluoromisonidazole 1fluorodopa F 18 1fludarabine phosphate 1etoposide phosphate 1eribulin 1dexamethasone acetate 1dexamethasone 21-phosphate 1clevudine 1ceritinib 1brivaracetam 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Brain Neoplasms × aldesleukin × Clear all
NCT02774291 2023-08-04

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Albert Einstein College of Medicine

Phase EARLY_PHASE1 Terminated
3 enrolled 6 charts
CNS

Brain Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡